Medical Cannabis for Trigeminal Neuralgia — Switzerland 2026
Trigeminal neuralgia is among the most intense human pains. On carbamazepine failure, cannabinoids are a documented option — cheaper for members.
Trigeminal neuralgia ("suicide disease") affects ~5,000 people in Switzerland. Carbamazepine/oxcarbazepine is first-line but 30 % fail or have severe side effects. Cannabinoids act via CB1 in trigeminal nuclei and reduce neuropathic pain. CannabisClub members: 50 CHF flat instead of 190.
What the studies show
Liang 2004 (preclinical): CB1 activation reduces trigeminal pain transmission in rat model.
Case series & cohorts 2018–2023: THC 5–15 mg daily reduced attack frequency and intensity in carbamazepine failure.
Preparations & dosing
THC oil 2.5 mg evenings, titrate to 10–15 mg daily in 2–3 doses.
CBD oil 25–50 mg twice daily — neuroprotective, potentiates THC analgesia.
Save as a CannabisClub member
Neurological cannabis consultations cost 190–290 CHF. Members: 50 CHF flat, titration plan included. Registration free.
FAQ
Does cannabis replace my carbamazepine?
Not as first-line. Add-on in insufficient efficacy or side effects. Discontinue only with neurologist.
What does membership save?
50 CHF instead of 190 CHF per consultation. Registration free.
Does insurance cover it?
In documented carbamazepine resistance, increasingly possible via art. 71a — we check.
Cannabis for Trigeminal Neuralgia — Prescription Switzerland 2026 (Members 50 CHF)